Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Randomized, controlled interventional trial to investigate the efficacy of amiloride for the treatment of edema in human nephrotic syndrome

    Summary
    EudraCT number
    2019-002607-18
    Trial protocol
    DE  
    Global end of trial date
    30 Apr 2023

    Results information
    Results version number
    v1(current)
    This version publication date
    27 Jun 2024
    First version publication date
    27 Jun 2024
    Other versions
    Summary report(s)
    Publication

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    AmiloridNS-01
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT05079789
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    University Hospital Tuebingen
    Sponsor organisation address
    Geissweg 3, Tuebingen, Germany, 72076
    Public contact
    Secretary's office Dep. Int.Med. IV, Univerity Hospital Tuebingen, +49 707129 83172,
    Scientific contact
    Secretary's office Dep. Int.Med. IV, Univerity Hospital Tuebingen, +49 707129 83172,
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    02 Feb 2024
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    30 Apr 2023
    Global end of trial reached?
    Yes
    Global end of trial date
    30 Apr 2023
    Was the trial ended prematurely?
    Yes
    General information about the trial
    Main objective of the trial
    Objective of the study is to prove the efficacy and superiority of amiloride for reduction of edema and overhydration in human nephrotic syndrome in comparison to standard medication with furosemide.
    Protection of trial subjects
    No further follow up is necessary for this Phase IIIB study after completion of the follow up period according to the study protocol.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    08 Jun 2020
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Germany: 20
    Worldwide total number of subjects
    20
    EEA total number of subjects
    20
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    17
    From 65 to 84 years
    3
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    -

    Pre-assignment
    Screening details
    -

    Pre-assignment period milestones
    Number of subjects started
    20
    Number of subjects completed
    20

    Period 1
    Period 1 title
    Period 1 (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Amiloride
    Arm description
    -
    Arm type
    Experimental

    Investigational medicinal product name
    Amiloride
    Investigational medicinal product code
    Other name
    Modamide®
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    initial dose 5 mg once daily, maximum dose 15 mg once daily

    Arm title
    Furosemide
    Arm description
    -
    Arm type
    Active comparator

    Investigational medicinal product name
    Furosemide
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    initial dose 40 mg once daily, maximum dose 120 mg once daily

    Number of subjects in period 1
    Amiloride Furosemide
    Started
    10
    10
    Completed
    10
    10

    Baseline characteristics

    Close Top of page

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Amiloride
    Reporting group description
    -

    Reporting group title
    Furosemide
    Reporting group description
    -

    Primary: Primary end point: decrease of overhydration (OH) at day 8

    Close Top of page
    End point title
    Primary end point: decrease of overhydration (OH) at day 8
    End point description
    decrease of overhydration (OH) at day 8
    End point type
    Primary
    End point timeframe
    8 days
    End point values
    Amiloride Furosemide
    Number of subjects analysed
    10
    10
    Units: % of extracellular water (ECW)
        median (inter-quartile range (Q1-Q3))
    1.95 (0.8 to 6.4)
    5.15 (0.9 to 8.3)
    Statistical analysis title
    Analysis of primary endpoint
    Comparison groups
    Amiloride v Furosemide
    Number of subjects included in analysis
    20
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.38
    Method
    t-test, 1-sided
    Confidence interval

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    23 days for everey subject.
    Assessment type
    Non-systematic
    Dictionary used for adverse event reporting
    Dictionary name
    CTCAE
    Dictionary version
    2012/C 302
    Reporting groups
    Reporting group title
    Amiloride
    Reporting group description
    -

    Reporting group title
    Furosemide
    Reporting group description
    -

    Serious adverse events
    Amiloride Furosemide
    Total subjects affected by serious adverse events
         subjects affected / exposed
    1 / 10 (10.00%)
    4 / 10 (40.00%)
         number of deaths (all causes)
    0
    0
         number of deaths resulting from adverse events
    0
    0
    Surgical and medical procedures
    delayed discharge from hospital due to macrohematuria after kidney biopsy
         subjects affected / exposed
    1 / 10 (10.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac disorders
    myocardial infarction
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 10 (10.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    pericardial effusion with in-hospital monitoring
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 10 (10.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal disorders
    abdominal pain with diarrhea with in-hospital treatment
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 10 (10.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Renal and urinary disorders
    AKI stage 2 with in-hospital treatment
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 10 (10.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Amiloride Furosemide
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    9 / 10 (90.00%)
    10 / 10 (100.00%)
    Surgical and medical procedures
    planned hospitalization for kidneybiopsy
         subjects affected / exposed
    2 / 10 (20.00%)
    3 / 10 (30.00%)
         occurrences all number
    2
    3
    Nervous system disorders
    dizziness
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    headache
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Gastrointestinal disorders
    nausea
         subjects affected / exposed
    2 / 10 (20.00%)
    0 / 10 (0.00%)
         occurrences all number
    2
    0
    Respiratory, thoracic and mediastinal disorders
    epistaxis
         subjects affected / exposed
    1 / 10 (10.00%)
    1 / 10 (10.00%)
         occurrences all number
    1
    1
    Hepatobiliary disorders
    elevated liver enzymes
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Skin and subcutaneous tissue disorders
    rash
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Renal and urinary disorders
    urinary infection
         subjects affected / exposed
    1 / 10 (10.00%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    hypervolemia (worsening)
         subjects affected / exposed
    1 / 10 (10.00%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Musculoskeletal and connective tissue disorders
    cramps of legs and hands
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Infections and infestations
    SARS CoV 2 infection
         subjects affected / exposed
    2 / 10 (20.00%)
    1 / 10 (10.00%)
         occurrences all number
    2
    1

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? No

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 06:05:19 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA